Conferences - Results from #9640

Viewing 9641-9660 of 11721 articles

ASCO GU 2017: Resection margins after radical cystectomy at academic versus community cancer centers. - Session Highlights

ASCO GU 2017: Characterizing the costs of complications after cystectomy: Can we target the primary drivers? - Session Highlights

ASCO GU 2017: Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. - Session Highlights

ASCO GU 2017: Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer - Session Highlights

ASCO GU 2017: Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC). - Session Highlights

ASCO GU 2017: Informed decision making (IDM) for prostate cancer (PCa) screening in a high-risk population. - Session Highlights

ASCO GU 2017: Optimal Selection of Front-Line Therapies for Metastatic Renal Cell Carcinoma - Session Highlights

ASCO GU 2017: A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). - Session Highlights

ASCO GU 2017: Evolving Treatment Using Tyrosine Kinase Inhibitors and Immunotherapy in Metastatic Renal Cell Carcinoma - Session Highlights

ASCO GU 2017: Adjuvant Therapy of Renal Cell Carcinoma: Current Controversies - Session Highlights

ASCO GU 2017: Imaging as Biomarker of Response in Advanced Renal Cell Carcinoma - Session Highlights

ASCO GU 2017: Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC) - Session Highlights

ASCO GU 2017: Evolution of circulating tumor DNA profile from 1st line to 2nd line therapy in metastatic renal cell carcinoma. - Session Highlights

ASCO GU 2017: Cryoablation of cT1 renal masses in the “healthy” patient: Early outcomes from Mayo Clinic. - Session Highlights

ASCO GU 2017: Comparative effectiveness of tumor response assessment methods: Standard-of-care versus computer-assisted response evaluation. - Session Highlights

ASCO GU 2017: How best to treat locally advanced penile cancer: radiation versus surgery - Session Highlights

ASCO GU 2017: Orphan Cancers with Opportunities for Improved Treatment: Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy - Session Highlights

ASCO GU 2017: Phase II Study Supports Potential For Genentech’s TECENTRIQ® (ATEZOLIZUMAB) PLUS AVASTIN® (BEVACIZUMAB) For People With Locally Advanced or Metastatic Renal Cell Carcinoma - Session Highlights

ASCO GU 2017: Intermediate-term outcomes from the DISSRM registry: A prospective analysis of active surveillance in patients with small renal masses. - Session Highlights

ASCO GU 2017: Use of Ablation in Small Renal Tumors - Session Highlights

478
479
480
481
482
483
484
485
486
487